# A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

> **NCT07670884** · PHASE3 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 675 (estimated)

## Conditions studied

- Chronic Management of Body Weight

## Interventions

- **DRUG:** HRS9531 Tablet
- **DRUG:** HRS9531 Tablet Placebo

## Key facts

- **NCT ID:** NCT07670884
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-24
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-11-30
- **Target enrollment:** 675 (ESTIMATED)
- **Last updated:** 2026-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670884, "A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*